New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System

An analysis of more than 16,000 VA patients who switched from HUMIRA to HADLIMA found a 1.3% switchback rate and estimated $132 million in savings. The report concerns this patient cohort; it does not provide a time period or broader company-level results.